Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + gemcitabine for advanced soft tissue sarcoma
MOH_2025-03-13_013971Phase 2Not yet recruiting
- Sponsor
- SELNET
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor and gemcitabine in soft tissue sarcoma (STS), leiomyosarcoma (LMS) and malignant peripheral nerve sheath tumor (MPNST), sponsored by SELNET. Primary endpoint: Progression-free status at 6 months. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
selinexorgemcitabine
03
Conditions
soft tissue sarcoma (STS)leiomyosarcoma (LMS)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on MOH_2025-03-13_013971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-13_013971.